Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness
Not yet recruiting
- Conditions
- Persistent Pulmonary Hypertension of Newborn
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 60
- Registration Number
- NCT06499363
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 220
- Registration Number
- NCT06355531
- Locations
- 🇬🇧
University of Cambridge, Cambridge, United Kingdom
🇺🇸The Neurology Center of Southern California - Carlsbad, Carlsbad, California, United States
🇺🇸UCSF Weill Institute for Neurosciences, San Francisco, California, United States
Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 201
- Registration Number
- NCT05866926
- Locations
- 🇪🇸
Hospital Universitari de Bellvitge, Barcelona, Spain
Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease
- Conditions
- Pulmonary HypertensionInterstitial Lung DiseaseCombined Pulmonary Fibrosis and Emphysema
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ferrer Internacional S.A.
- Registration Number
- NCT05572996
Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 300
- Registration Number
- NCT05178810
- Locations
- 🇳🇱
UMC Utrecht, Utrecht, Netherlands
🇫🇷CHU Nice, Nice, France
🇫🇷Hôpital de la Salpêtrière, Paris, France
Clinical Trial in Children Between 3 Months and 14 Years Old to Evaluate the Efficacy and Safety of Gelatin Tannate in the Treatment of Acute Diarrhea (INDIGO)
Phase 3
Completed
- Conditions
- Diarrhea
- Interventions
- Combination Product: placebo + ORS + Zinc supplementationCombination Product: Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 150
- Registration Number
- NCT04065529
- Locations
- 🇸🇳
Niakhar Center IRD, Dakar, Senegal
Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 48
- Registration Number
- NCT02917291
- Locations
- 🇪🇸
Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸Hospital Universitario Virgen del Rocío, Sevilla, Spain
Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy
Phase 2
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 528
- Registration Number
- NCT02791958
- Locations
- 🇺🇸
Central Alabama Research, Birmingham, Alabama, United States
🇺🇸Meridien Research, St. Petersburg, Florida, United States
🇺🇸Diagnostics Research Group, San Antonio, Texas, United States
Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting
Phase 4
Completed
- Conditions
- Agitation
- Interventions
- Device: Staccato® Delivery System Loxapine (ADASUVE®)
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 323
- Registration Number
- NCT02525991
- Locations
- 🇪🇸
Ferrer Internacional S.A., Barcelona, Spain
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 412
- Registration Number
- NCT02090764
- Locations
- 🇵🇷
Caparra Internal Medicine Center, Rio Grande, Puerto Rico
© Copyright 2025. All Rights Reserved by MedPath